Aradigm Corporation

Industry:	Pharmaceuticals, Drug Manufacturing & Research, Medical Devices & Equipment
Revenues:	$961,000
Employees:	54

Description

Aradigm Corporation is a specialty pharmaceutical company focused on the development and commercialization of a selection of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Product candidates in development include both the Company's own products and products under development with collaborators. They consist of approved drugs combined with Aradigm's inhalation delivery and/or formulation technologies. As of December 31, 2007, the Company had five respiratory product candidates in development: treatments for cystic fibrosis, bronchiectasis, inhalation anthrax, smoking cessation treatment, and, in collaborations with other companies, pulmonary arterial hypertension and asthma and other chronic obstructive diseases of airways.
(Source: 10-K)

Products & Services

drug delivery systems, specialty pharmaceutical

View More Statistics

Site Statistics

Monthly Unique Visitors:	1,077
Site Rank:	984,805
Trust Rating:	Neutral
Stats by

News Archive

Aradigm Presents Data Demonstrating Significant Antibacterial Concentrations and Effects in Non-Cystic Fibrosis Bronchiectasis Patients Following Administration of its Once-Daily Inhaled Liposomal Ciprofloxacin. Business Wire; 9/14/2009 Aradigm is presenting results from its Phase 2a...ERS) Annual Congress. Additionally, Aradigm is presenting summary data on the pharmacokinetics...healthy volunteers. HAYWARD, Calif. -- Aradigm Corporation (OTCBB: ARDM) ("Aradigm... ...more

Aradigm to Present at the 8th Annual BIO Investor Forum on October 28. Biotech Week; 11/4/2009 Aradigm Corporation (OTCBB:ARDM) (the "Company...30 p.m. Eastern time) (see also Aradigm Corporation). The event will be held...webcast and slide presentation at www.aradigm.com. An archived presentation will be... ...more

Novo Nordisk Agrees To $55M For Aradigm's Insulin Program. BIOWORLD Today; 11/3/2009 ...West Coast Editor Almost six months after Aradigm Corp. and partner Novo Nordisk A/S...system (IDMS) program for $55 million. Aradigm's stock (NASDAQ:ARDM) closed Wednesday...president and CEO of Hayward, Calif.-based Aradigm. The bad news from the Phase III trial... ...more